Results 61 to 70 of about 15,316 (190)

BUTYLCHLORAL IN TRIGEMINAL NEURALGIA [PDF]

The American Journal of the Medical Sciences, 1889
n ...
openaire   +1 more source

Regional Nerve Blocks and OnabotulinumtoxinA in the Management of Trigeminal Trophic Syndrome: A Case Report of a Novel Multimodal Approach

Oral Surgery, EarlyView.
ABSTRACT Objective Trigeminal trophic syndrome (TTS) is a rare condition caused by trigeminal nerve injury, classically characterized by anaesthesia, paresthesia and facial ulceration. We present two cases of TTS successfully managed with regional nerve blocks and onabotulinumtoxinA. Methods Two patients—a 54‐year‐old woman and a 65‐year‐old man—with a
Shamin Masrour, Rhea Sudhakaran
wiley   +1 more source

Therapeutic potential of spexin in diabetic neuropathy: Insights from in vitro and in vivo models

Experimental Physiology, EarlyView.
Abstract The present study investigated the therapeutic potential of spexin (SPX) on both in vitro and in vivo models of diabetic neuropathy (DN). A total of 40 male BALB/c mice were randomly allocated into four experimental groups (n = 10 per group): a normoglycaemic control, an untreated DN group and two SPX treatment groups (DN+SPX‐12.5 and DN+SPX ...
Mehmet Refik Bahar, Seval Ulku Orhan, Cigdem Tekin, Asli Taslidere, Mete Ozcan, Suat Tekin   +5 more
wiley   +1 more source

TRESK alleviates trigeminal neuralgia induced by infraorbital nerve chronic constriction injury in rats

Molecular Pain, 2019
Trigeminal neuralgia commonly results in pain behaviors and cognitive impairment. Convincing evidence suggests that TWIK-related spinal cord K + (TRESK) exerts antinociceptive and neuroprotective effects.
Yuanyuan Li, Hena Jiao, Wenan Ren, Fei Ren   +3 more
doaj   +1 more source

Prognostic Factors for Postoperative Complications. An Aggregate Protocol for 10 Observational Studies From the Danish TRIPLE‐A Cohort of 1.2 Million Surgeries

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background Postoperative complications substantially increase morbidity, mortality and healthcare costs. Understanding prognostic factors is essential for risk stratification, targeted prevention strategies, and development of prediction models.
Anders Peder Højer Karlsen, Asta Prescott, Caroline Folkersen, Jens Laigaard, Atena Saito, Caroline Lando Klammer, Mik Wetterslev, Emil Ipsen Ørskov, Mathilde Fahrendorff, Rebecca Kiær, Helene Holm Laigaard, Nichlas Hovmand, Lars Hyldborg Lundstrøm, Sebastian Buhl Rasmussen, Anders Kehlet Nørskov, Markus Harboe Olsen   +15 more
wiley   +1 more source

Effectiveness and Tolerability of Topical Amitriptyline 10% Plus Lidocaine 2% Gel in Adults With Post‐Traumatic Trigeminal Neuropathic Pain: A Real‐World Evidence Study

Journal of Oral Rehabilitation, Volume 53, Issue 8, Page 1550-1561, August 2026.
A compounded amitriptyline 10% plus lidocaine 2% mucoadhesive gel was associated with substantial pain improvement and favourable tolerability in adults with post‐traumatic trigeminal neuropathic pain (PTNP). These findings support targeted mucosal delivery as a promising practical local option and a potential medication‐sparing strategy, particularly ...
Ashley Lebel, Imen Stambouli, Yves Boucher   +2 more
wiley   +1 more source

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

Arthritis Care &Research, Volume 78, Issue 7, Page 860-874, July 2026.
Objective Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies.
Anahita Deboo, Robert Fox, Katherine M. Hammitt, Julie Frantsve‐Hawley, Matthew C. Baker, Stamatina Danielides, Eduardo De Sousa, Brent P. Goodman, Jennifer K. King, Steven Mandel, Ghaith Noaiseh, Pantelis P. Pavlakis, George Sarka, R. Hal Scofield, Arun Varadhachary, Daniel J. Wallace, Matt Makara, Nancy Carteron, Steven Carsons, in collaboration with the Consensus Expert Panel (CEP) members, G. Alden Adkins, Brittany Adler, Hossein Ansari, Senada Arabelovic, Alan Baer, Denis Balaban, Shamik Bhattacharyya, Evelyn Bromet, Krishna Chaganti, Kamal Chemali, Melissa Cortez, Schartess Culpepper, Paul Dellaripa, Dana Direnzo, Daniel El Bogdadi, Robert Fearon, Mehrnez Fischbach, Judi Furlong, Christopher Gibbons, Rachael Gordon, Thomas Grader Beck, Syed Haider, Larry Hollenbeck, Chadwick R. Johr, Stuart S. Kassan, Brian King, Octavia Kincaid, Eugene Kissin, Vasileios Kyttaris, Lindsay Lally, Brandon M. Law, Janet Lewis, Scott M. Lieberman, Amanda Lusa, Joseph Lutt, Rashmi Maganti, Arthur M. Mandelin, Sara McCoy, Kerry Neall, Timothy Niewold, Anne Louise Oaklander, Ruben A. Peredo‐Wende, Lynn Petruzzi, Mark A. Porter, Guada Respicio Duque, Tania Reyna, Nathaniel M. Robbins, Elliot D. Rosenstein, Laura Rosow, Breanna Ruthrauff, Amit Sachdev, Nora Sandorfi, Sarah Schafer, Elena Schiopu, Chokkalingam Siva, Daniel Small, Sara M. Stern, Lauren Stiles, Susan Stoddard, Jinny Tavee, Donald Thomas, Edward L. Treadwell, Nagagopal Venna, Steven Vernino, Frederick B. Vivino, Brittany Weber, Sepideh Yadollahi, Huiying Yu, Scott Zashin   +88 more
wiley   +1 more source

Trigeminal Neuralgia [PDF]

Journal of Oral and Maxillofacial Surgery, 2021
openaire   +2 more sources

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2183-2192, July 2026.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan   +7 more
wiley   +1 more source

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 1957-1976, July 2026.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source